Navigation Links
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
Date:5/14/2009

Phase 1: Encouraging Results Observed in CLL Patients Treated With Low Doses of TRU-016

Preclinical Efficacy: TRU-016 is Additive or Synergistic in Combination with Established Therapeutics

Preclinical Mechanism Apoptosis in CLL Cells Occurs Via Distinct Mechanism Compared With Other Therapeutics

SEATTLE, May 14 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the acceptance of three data presentations on its proprietary product candidate, TRU-016, that will be given at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting May 29 through June 2 in Orlando, Fla. The presentations will include positive data from a Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), a preclinical study demonstrating the additive or synergistic effects of TRU-016 in combination with other therapeutic drugs for the treatment of non-Hodgkin's lymphoma (NHL), and a preclinical study evaluating the effect of TRU-016 on direct apoptosis in CLL cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Abstract 3017 (May 31, 2009): A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)), in Relapsed and Refractory CLL -- Early Promising Clinical Activity

As of the abstract submission, 10 patients enrolled in the Phase 1 trial had received intravenous doses ranging from 0.03 mg/kg to 3.0 mg/kg of TRU-016. Initial data from the study demonstrates the safety and early signs of efficacy of TRU-016 as shown by a reduction in tumor lymphocyte blood counts, reduction in lymph node and spleen size, and/or an improvement in hematopoiesis, or the production of red blood c
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
2. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
3. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
4. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
7. Trubion Announces Presentations at Upcoming Investor Conferences
8. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 02, 2014 IAL is pleased ... of its report on the markets for rigid ... examines the developments encountered in the global market ... , Full Report With TOC @ ... trends driving the demand. The study presents production ...
(Date:10/2/2014)... MO (PRWEB) October 02, 2014 Permian ... business in the St. Louis, Missouri, area on October ... has become a leading plastic injection molder in the ... machines and is a supplier to many Fortune 500 ... customer support every step of the way, from concept ...
(Date:10/2/2014)... de 2014 Laborie Medical Technologies, Inc. ("LABORIE"), ... ha completado la adquisición de Unisensor AG y Unisensor ... sede central sita en Wiesendangen, Suiza, y lleva a ... New Hampshire . Unisensor está especializada en el ... para evaluar la presión y valores de pH para ...
(Date:10/2/2014)... -- SIRO Clinpharm, an award-winning Clinical Research ... Annual Conference of the Society for Clinical Data Management ... where they were invited to speak at three sessions. ... to support fraud detection, ,clinical data management,s role in ... together as virtual and integrated teams,. The award-winning streak ...
Breaking Biology Technology:Global Overview of the Spray Polyurethane Foam (SPF) & One Component Foam (OCF) : Industry Analysis, Size, Share, Trends And Forecast Research Report by Researchmoz 2Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2LABORIE adquiere Unisensor AG y Unisensor USA, Inc. 2SIRO Clinpharm Showcases Biometrics Capabilities at the SCDM 2014 Annual Conference in Las Vegas 2
... 15 MannKind,Corporation (Nasdaq: MNKD ), focused on ... today that it,will present at the UBS Global Life ... (ET) at the Grand Hyatt in New York., ... web cast of the,presentation in the Investor Relations section ...
... Join as Company Enters Commercialization Phase, NAPLES, ... TO ETHANOL(TM), the most advanced third generation biofuels,technology, ... with the,appointments Greg Schlicht as Senior Vice President ... as Senior Program Manager., Mr. Schlicht will ...
... Sept. 15 Insmed Inc. (Nasdaq:,INSM) a developer ... Allan, Ph.D., CEO of Insmed, will present at ... will be discussing,the Company,s perspective on the potential ... will also Chair a panel on this topic ...
Cached Biology Technology:Algenol Biofuels Further Strengthens Team With Key Appointments 2Insmed to Present at Biosimilars 2008 Conference 2
(Date:9/30/2014)... 2014--Sea monkeys have captured the popular attention of both ... life cycle -- sold as dehydrated eggs, these tiny ... more than a tank of salt water. , ... other zooplankton, brine shrimp vertically migrate in large groups ... the surface at night and retreating deeper during the ...
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
(Date:9/30/2014)... can live in almost any aquatic environment on Earth, ... many species are pushed to the limit. The amount ... prove critical for how different species cope in the ... University of Gothenburg, published in the scientific journal ... change continues apace thanks to increasing levels of greenhouse ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Shape up quickly -- applies to fish, too! 2
... the Bellvitge Biomedical Research Institute (IDIBELL) at the ... into how the IDPN nitrile causes neurological syndromes ... (ALS), a severe neuromuscular degenerative disease. The study, ... in Neuropathology and Applied Neurobiology journal. ...
... to dust off the garden tables and chairs. But garden furniture ... covered with a slimy film of algae, moss, bacteria and fungi ... hoping that they can solve this problem by incorporating titanium dioxide ... adding a little bit of sunlight. When these titanium dioxide molecules ...
... German . Zebrafish share most organ systems ... the causes of human diseases like cancer or heart diseases. ... With the European Zebrafish Resource Center (EZRC), Karlsruhe Institute of ... such lines in Europe. The EZRC is funded jointly by ...
Cached Biology News:Poisoning from industrial compounds can cause similar effects to ALS 2Cleaning with sunlight 2Zebrafish -- the stars of biomedicine 2